Journal for ImmunoTherapy of Cancer · 2023 · 40 citations · 16 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor MicroenvironmentCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsT Cell Responses To TumorsTumor Immune MicroenvironmentTumor-infiltrating LymphocytesCell InfiltrationConsensusImmune Checkpoint Inhibitor ResponseImmune Checkpoint Inhibitor TherapyImmune DesertsImmune-excluded TumorsPatient Outcomes MeasurementRegulatory T Cell Infiltration
Checkpoint inhibitors represent an effective treatment approach for a variety of cancers through their inhibition of immune regulatory pathways within the tumor microenvironment (TME). Unfortunately only a minority of patients with cancer achieve clinical benefit from immunotherapy, with the TME emerging as an important predictor of outcomes and sensitivity to therapy. The extent and pattern of T-cell infiltration can vary prominently within/across tumors and represents a biological continuum. Three immune profiles have been identified along this continuum: 'immune-desert' or 'T-cell cold' phenotype, 'immune-active', 'inflamed', or 'T-cell hot' phenotype, and 'immune excluded' phenotype. Of the three profiles, immune excluded remains the most ill-defined with no clear, universally accepted definition even though it is commonly associated with lack of response to immune checkpoint inhibitors and poor clinical outcomes. To address this, 16 multidisciplinary cancer experts from around the world were invited to participate in a symposium using a three-round modified Delphi approach. The first round was an open-ended questionnaire distributed via email and the second was an in-person discussion of the first round results that allowed for statements to be revised as necessary to achieve a maximum consensus (75% agreement) among the rating committee (RC). The final round questionnaire was distributed to the RC via email and had a 100% completion rate. The Delphi process resulted in moving us closer to a consensus definition for immune exclusion that is practical, clinically pertinent, and applicable across a wide range of cancer histologies. A general consensus of the role of immune exclusion in resistance to checkpoint therapy and five research priorities emerged from this process. Together, these tools could help efforts designed to address the underlying mechanisms of immune exclusion that span cancer types and, ultimately, aid in the development of treatments to target these mechanisms to improve patient outcomes.
16
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Jérôme Galon, Anne Costes, Fátima Sánchez‐Cabo et al. · Science · 2006 · 6.5K citations
Medicine, Immunology, Oncology +17
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz et al. · Nature · 2014 · 5.3K citations
Medicine, Immunology, Oncology +16
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu, Jesse M. Zaretsky, Siwen Hu‐Lieskovan et al. · Nature · 2018 · 332 citations · Full text
Medicine, Cancer Biology, Oncology +13
Topography of cancer-associated immune cells in human solid tumors
Jakob Nikolas Kather, Meggy Suarez‐Carmona, Pornpimol Charoentong et al. · eLife · 2018 · 281 citations · Full text
Medicine, Immunology, Oncology +17